Notícias e Atividades da Intra-Cellular Therapies

Intra-Cellular Therapies é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Intra-Cellular Therapies é uma empresa listada sob o símbolo ITCI (US).

Fusão, aquisição e financiamento envolvendo Intra-Cellular Therapies.

• Johnson & Johnson has announced the acquisition of Intra-Cellular Therapies  (publicado em 13 de janeiro de 2025).

Veja o organograma con seus 15 executivos principais

Biografias mais buscadas da Intra-Cellular Therapies

• Sharon Mates, President, Chairman and Chief Executive Officer
• Rene Salas, Director
• Rory Riggs, Director

Criar um alerta
para seguir os movimentos de executivos da Intra-Cellular Therapies.

Intra-Cellular Therapies possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of Verve Therapeutics  (publicado em 17 de junho de 2025).
• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Intra-Cellular Therapies

• Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast | Intra-Cellular Therapies Inc.
• Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress | Intra-Cellular Therapies Inc.
• View more press releases Close

Redes sociais sobre Intra-Cellular Therapies

• Intra-Cellular Therapies na Wikipedia, Google News e Yahoo Finance
• Intra-Cellular Therapies na LinkedIn, Twitter e YouTube